Successful treatment with ABL tyrosine kinase inhibitor for patients with acute myeloid leukemia with BCR-ABL1

Successful treatment with ABL tyrosine kinase inhibitor for patients with acute myeloid leukemia with BCR-ABL1

Acute myeloid leukemia (AML) with BCR-ABL1 is rare and has a poor prognosis with conventional chemotherapy or ABL tyrosine kinase inhibitors (TKIs) alone. We reported a case of AML with BCR-ABL1 patient who was successfully treated with dasatinib alone; additionally, we previously reported another c...

Full description

Bibliographic Details
Main Authors: Asako Takeuchi, Toshinori Kondo, Taizo Tasaka, Seiko Yamada, Tadashi Hirose, Hirofumi Fukuda, Risa Shimizu, Yoshiko Matsuhashi, Eisei Kondo, Hideho Wada
Format: Article
Language:English
Published: Elsevier 2021-01-01
Series:Leukemia Research Reports
Subjects:
Acute myeloid leukemia
BCR-ABL1
Philadelphia chromosome
Tyrosine kinase inhibitor
Online Access:http://www.sciencedirect.com/science/article/pii/S221304892030039X

Internet

http://www.sciencedirect.com/science/article/pii/S221304892030039X

Similar Items